Zura Bio Ltd. is a clinical-stage biotechnology company that engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.
相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Zura Bio is advancing tibulizumab, a bispecific antibody targeting IL-17A and BAFF, through two Phase 2 trials for autoimmune inflammatory disorders. - The company expects Phase 2 data from hidradenitis suppurativa trials in Q4 2024, with 225 patients enrolled and primary endpoint measuring abscess and nodule count reduction. - A second Phase 2 trial in systemic sclerosis is planned for first half 2027, focusing on patients with diffuse subtype and using modified Rodnan skin score as primary endpoint. - The bispecific was licensed from Eli Lilly in 2023 and engineered using sequences from tabalumab and ixekizumab, with Phase 1 data showing low immunogenicity in 78 subjects.
- Zura Bio has initiated the Phase II TibuSHIELD trial evaluating tibulizumab, a first-of-its-kind dual inhibitor targeting both BAFF and IL-17A pathways in patients with moderate to severe hidradenitis suppurativa. - The global, randomized, double-blind, placebo-controlled study will enroll approximately 180 patients across the US, Canada, and Europe, with topline efficacy results expected in Q3 2026. - This trial represents Zura Bio's second Phase II study for tibulizumab, following the December launch of TibuSURE for systemic sclerosis, advancing their portfolio of treatments for severe inflammatory diseases.
- Zura Bio has initiated a global Phase 2 trial, TibuSURE, to evaluate tibulizumab for treating systemic sclerosis (SSc) in adults, marking a significant step in addressing this complex autoimmune disease. - The TibuSURE study is designed as a double-blind, placebo-controlled trial involving approximately 80 participants with early diffuse cutaneous SSc, and includes an open-label extension. - Tibulizumab, a bispecific dual-antagonist antibody, targets both IL-17A and BAFF pathways, offering a novel approach compared to single-pathway inhibition, which has shown limited efficacy. - The primary endpoint of the TibuSURE trial is the modified Rodnan Skin Score (mRSS), with secondary endpoints assessing lung disease, physical function, and overall response in systemic sclerosis.
